These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 19041433

  • 1. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
    Buijs JT, Que I, Löwik CW, Papapoulos SE, van der Pluijm G.
    Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
    Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ, Dunstan CR.
    Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
    [Abstract] [Full Text] [Related]

  • 3. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
    Strube A, Hoffmann J, Stepina E, Hauff P, Klar U, Käkönen SM.
    Clin Cancer Res; 2009 Jun 01; 15(11):3751-9. PubMed ID: 19470728
    [Abstract] [Full Text] [Related]

  • 4. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis.
    Ooi LL, Zheng Y, Zhou H, Trivedi T, Conigrave AD, Seibel MJ, Dunstan CR.
    Bone; 2010 Oct 01; 47(4):795-803. PubMed ID: 20638491
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
    Liu J, Xu K, Wen G, Guo H, Li S, Wu X, Dai R, Sheng Z, Liao E.
    Bone; 2008 May 01; 42(5):950-9. PubMed ID: 18337202
    [Abstract] [Full Text] [Related]

  • 6. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.
    Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ.
    Clin Exp Metastasis; 2006 May 01; 23(1):19-31. PubMed ID: 16715352
    [Abstract] [Full Text] [Related]

  • 7. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
    Martin CK, Werbeck JL, Thudi NK, Lanigan LG, Wolfe TD, Toribio RE, Rosol TJ.
    Cancer Res; 2010 Nov 01; 70(21):8607-16. PubMed ID: 20959474
    [Abstract] [Full Text] [Related]

  • 8. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
    Greiner S, Kadow-Romacker A, Schmidmaier G, Wildemann B.
    J Biomed Mater Res A; 2009 Oct 01; 91(1):288-95. PubMed ID: 18980195
    [Abstract] [Full Text] [Related]

  • 9. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC.
    Breast Cancer Res Treat; 2012 Oct 01; 135(3):771-80. PubMed ID: 22926264
    [Abstract] [Full Text] [Related]

  • 10. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
    Sasaki A, Alcalde RE, Nishiyama A, Lim DD, Mese H, Akedo H, Matsumura T.
    Cancer Res; 1998 Feb 01; 58(3):462-7. PubMed ID: 9458090
    [Abstract] [Full Text] [Related]

  • 11. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
    de Molon RS, Shimamoto H, Bezouglaia O, Pirih FQ, Dry SM, Kostenuik P, Boyce RW, Dwyer D, Aghaloo TL, Tetradis S.
    J Bone Miner Res; 2015 Sep 01; 30(9):1627-40. PubMed ID: 25727550
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
    Ohba T, Cole HA, Cates JM, Slosky DA, Haro H, Ando T, Schwartz HS, Schoenecker JG.
    J Bone Miner Res; 2014 Jun 01; 29(6):1431-45. PubMed ID: 24443409
    [Abstract] [Full Text] [Related]

  • 13. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
    Haider MT, Holen I, Dear TN, Hunter K, Brown HK.
    Bone; 2014 Sep 01; 66(100):240-50. PubMed ID: 24971713
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T.
    Cancer Res; 1995 Aug 15; 55(16):3551-7. PubMed ID: 7627963
    [Abstract] [Full Text] [Related]

  • 15. Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice.
    Sheng ZF, Xu K, Ma YL, Liu JH, Dai RC, Zhang YH, Jiang YB, Liao EY.
    Osteoporos Int; 2009 Jan 15; 20(1):151-9. PubMed ID: 18496637
    [Abstract] [Full Text] [Related]

  • 16. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo.
    van der Pluijm G, Que I, Sijmons B, Buijs JT, Löwik CW, Wetterwald A, Thalmann GN, Papapoulos SE, Cecchini MG.
    Cancer Res; 2005 Sep 01; 65(17):7682-90. PubMed ID: 16140935
    [Abstract] [Full Text] [Related]

  • 17. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
    Rucci N, Capulli M, Ventura L, Angelucci A, Peruzzi B, Tillgren V, Muraca M, Heinegård D, Teti A.
    J Bone Miner Res; 2013 Sep 01; 28(9):1912-24. PubMed ID: 23559035
    [Abstract] [Full Text] [Related]

  • 18. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
    Li X, Liao J, Park SI, Koh AJ, Sadler WD, Pienta KJ, Rosol TJ, McCauley LK.
    Bone; 2011 Jun 01; 48(6):1354-61. PubMed ID: 21419883
    [Abstract] [Full Text] [Related]

  • 19. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ.
    Cancer Res; 2001 Jun 01; 61(11):4432-6. PubMed ID: 11389072
    [Abstract] [Full Text] [Related]

  • 20. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
    Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL, Holen I.
    Clin Cancer Res; 2014 Jun 01; 20(11):2922-32. PubMed ID: 24687923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.